NANETS/SNMMI consensus statement on patient selection and appropriate use of 177Lu-DOTATATE peptide receptor radionuclide therapy
MATERIALS AND METHODS Systematic Review To inform the development of these
guidelines, a systematic review of evidence was performed. We followed the Preferred …
guidelines, a systematic review of evidence was performed. We followed the Preferred …
Therapeutic strategies for neuroendocrine liver metastases
A Frilling, AK Clift - Cancer, 2015 - Wiley Online Library
Patients who have neuroendocrine tumors frequently present with liver metastases. A wide
panel of treatment options exists for these patients. Liver resection with curative intent …
panel of treatment options exists for these patients. Liver resection with curative intent …
177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival …
Background The primary analysis of the phase 3 NETTER-1 trial showed significant
improvement in progression-free survival with 177 Lu-Dotatate plus long-acting octreotide …
improvement in progression-free survival with 177 Lu-Dotatate plus long-acting octreotide …
[HTML][HTML] Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
J Strosberg, G El-Haddad, E Wolin… - … England Journal of …, 2017 - Mass Medical Soc
Background Patients with advanced midgut neuroendocrine tumors who have had disease
progression during first-line somatostatin analogue therapy have limited therapeutic options …
progression during first-line somatostatin analogue therapy have limited therapeutic options …
Efficacy and safety of high-specific-activity 131I-MIBG therapy in patients with advanced pheochromocytoma or paraganglioma
DA Pryma, BB Chin, RB Noto, JS Dillon… - Journal of Nuclear …, 2019 - Soc Nuclear Med
Patients with metastatic or unresectable (advanced) pheochromocytoma and
paraganglioma (PPGL) have poor prognoses and few treatment options. This multicenter …
paraganglioma (PPGL) have poor prognoses and few treatment options. This multicenter …
The North American neuroendocrine tumor society consensus guidelines for surveillance and medical management of pancreatic neuroendocrine tumors
This article is the result of the North American Neuroendocrine Tumor Society consensus
conference on the medical management of pancreatic neuroendocrine tumors from July 19 …
conference on the medical management of pancreatic neuroendocrine tumors from July 19 …
213Bi-DOTATOC receptor-targeted alpha-radionuclide therapy induces remission in neuroendocrine tumours refractory to beta radiation: a first-in-human experience
C Kratochwil, FL Giesel, F Bruchertseifer… - European journal of …, 2014 - Springer
Purpose Radiopeptide therapy using a somatostatin analogue labelled with a beta emitter
such as 90 Y/177 Lu-DOTATOC is a new therapeutic option in neuroendocrine cancer …
such as 90 Y/177 Lu-DOTATOC is a new therapeutic option in neuroendocrine cancer …
Dose mapping after endoradiotherapy with 177Lu-DOTATATE/DOTATOC by a single measurement after 4 days
H Hänscheid, C Lapa, AK Buck… - Journal of Nuclear …, 2018 - Soc Nuclear Med
Dosimetry of organs and tumors helps to assess risks and benefit of treatment with 177Lu-
DOTATATE/DOTATOC. However, it is often not performed in clinical routine because of …
DOTATATE/DOTATOC. However, it is often not performed in clinical routine because of …
[HTML][HTML] Results and adverse events of personalized peptide receptor radionuclide therapy with 90Yttrium and 177Lutetium in 1048 patients with neuroendocrine …
RP Baum, HR Kulkarni, A Singh, D Kaemmerer… - Oncotarget, 2018 - ncbi.nlm.nih.gov
Methods In our center, 2294 patients were screened between 2004 and 2014 by 68 Ga
somatostatin receptor (SSTR) PET/CT. Intention to treat analysis included 1048 patients …
somatostatin receptor (SSTR) PET/CT. Intention to treat analysis included 1048 patients …
Subacute haematotoxicity after PRRT with 177Lu-DOTA-octreotate: prognostic factors, incidence and course
H Bergsma, MW Konijnenberg, BLR Kam… - European journal of …, 2016 - Springer
Purpose In peptide receptor radionuclide therapy (PRRT), the bone marrow (BM) is one of
the dose-limiting organs. The accepted dose limit for BM is 2 Gy, adopted from 131 I …
the dose-limiting organs. The accepted dose limit for BM is 2 Gy, adopted from 131 I …